Psoriatic Arthritis News

Treatment with apremilast alone is effective in patients with oligoarticular psoriatic arthritis, according to data published in The Journal of Rheumatology.

Treatment with brodalumab resulted in rapid and significant improvement in the signs and symptoms of psoriatic arthritis, compared with a placebo, according to data published in the Annals of the Rheumatic Diseases.

Patients with autoimmune rheumatic diseases are less likely to avoid an office visit or laboratory tests due to COVID-19 and were more likely to have telehealth visits, according to a speaker at ACR Convergence 2020.

Joint care by a dermatologist, rheumatologist and other specialists can mitigate the “accelerated trajectory of comorbidities” that can often happen in patients with psoriatic disease, according to a presenter at ACR 2020.

Among patients with psoriatic arthritis, daily upadacitinib doses of either 15 or 30 mg improved musculoskeletal symptoms, psoriasis, physical function, pain, fatigue and radiographic progression, according to a speaker at ACR Convergence.

Patients with psoriatic arthritis and obesity had lower disease activity with a very low energy liquid diet, according to a study published in Arthritis Research & Therapy.

Patients with systemic autoimmune rheumatic diseases who contract COVID-19 may have a higher risk for end-organ failure than those without such diseases, according to a speaker at ACR Convergence 2020.

While the rheumatology community often finds itself behind other specialties in head-to-head trials of drugs or drug classes, new data may help clinicians in decision-making, according to a presenter at ACR 2020.

Therapeutic drug monitoring, in which treatments were individually assessed and reviewed, failed to improve remission for patients with a variety of rheumatic diseases who started infliximab, according to a speaker at ACR Convergence.

A drug comprised of a nonliving single strain commensal microbe showed signs of safe and effective treatment of mild to moderate psoriasis, according to a presentation at the European Academy of Dermatology and Venereology virtual congress.